Caregen (CEO Yongji Jeong), a synthetic peptide-based biotechnology company, successfully concluded the 'Bio Korea 2025' exhibition held at COEX in Seoul from the 7th to the 9th. At this event, Caregen focused on the differentiation and commercial expansion potential of its peptide platform technology, drawing great attention from domestic and international bio industry insiders.
The product that received the most attention was Korglutide, a next-generation GLP-1 analog developed by Caregen. Caregen is currently conducting a clinical trial in India with a total of 100 subjects using the same protocol as the representative GLP-1 analog drugs semaglutide (trade name Wigobi) and liraglutide (trade name Saxenda). According to the interim results data (Interim Report), the test group taking Korglutide demonstrated an excellent weight loss effect, with an average weight loss of 9.46% (-8.15 kg) over 12 weeks. Korglutide is an oral dosage form based on a short peptide structure consisting of 7 amino acids, and showed a weight loss effect centered on body fat while causing relatively little muscle loss. Its low side effects and excellent production efficiency were highlighted as strengths that complement the limitations of existing GLP-1 preparations.
In addition, Caregen also introduced in detail the mechanisms of action and efficacy of its main pipelines, including 'ProGsterol' and 'MyoKi', which have completed registration as NDI (New Dietary Ingredient) with the US FDA, and 'CG-P5', a candidate for the treatment of wet macular degeneration. It was also noticeable that the entire booth was systematically organized so that visitors could easily understand the functions and scientific background of the products.
A foreign PE (Private Equity) official who visited the site said, “Now that GLP-1 drugs are becoming popular, Coglutide is a game changer that can change the market landscape as an oral dosage form with pharmaceutical-level efficacy.” He added, “Coglutide’s approach of presenting obesity not as a simple treatment but as a health solution that can be continuously managed in daily life is a strategic attempt to change the existing industry frame.”
Jeong Yong-ji, CEO of Caregen, said, “Coglutide is a peptide-based healthy weight management solution with the potential to be widely positioned in the global market,” adding, “Approaching it as a health functional food is a strategy that can open up new market opportunities for maintaining a healthy lifestyle rather than the disease treatment market.”
He continued, “As the GLP-1 series drug market is growing rapidly and competition is fierce, direct comparison with existing drugs could actually be detrimental to brand positioning.” He emphasized, “Caregen is pursuing a differentiated approach that provides a solution to manage weight naturally in daily life without having to go to the hospital.”
He also added, “We are planning a step-by-step strategy to initially launch Coglutide as a health functional food or wellness brand to secure consumer responses and actual usage data, and then use this as a basis to accelerate future therapeutic development and global market expansion.” He also said, “We are actively reviewing the possibility of expanding it to lifestyle products that span all generations, including inner beauty.”
Meanwhile, Caregen plans to participate in 'Vitafoods Europe 2025', the world's largest functional health food raw material fair, held in Barcelona, Spain from the 20th to the 22nd.
- See more related articles
You must be logged in to post a comment.